M. Cheng

Efficacy and Safety of SER120 Nasal Spray in Patients with Nocturia: Pooled Analysis of 2 Randomized, Double‐Blind, Placebo Controlled, Phase 3 Trials

R. Dmochowski, A. Wein, S. Macdiarmid, 2018, The Journal of urology.

Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study

P. Rutgeerts, D. Hommes, C. Bernstein, 2010, Inflammatory bowel diseases.

A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon γ antibody, in patients with moderate to severe Crohn’s disease

P. Rutgeerts, D. Hommes, G. Van Assche, 2005, Gut.

A comprehensive preclinical study supporting clinical trial of oncolytic chimeric poxvirus CF33-hNIS-anti-PD-L1 to treat breast cancer

Xiwei Wu, S. Chaurasiya, Y. Fong, 2021, Molecular therapy. Methods & clinical development.

Fontolizumab in moderate to severe Crohn's disease: A phase 2, randomized, double‐blind, placebo‐controlled, multiple‐dose study

P. Rutgeerts, D. Hommes, C. Bernstein, 2010, Inflammatory bowel diseases.